|
Dr. Wild is a general partner of Bows Pharmaceuticals AG. He was chairman of MedPointe, Inc. a specialty pharmaceutical company, from September 2001 until its merger with Meda AB in August 2007, and he served as MedPointe's chief executive officer from 2001 to 2006. Prior to joining MedPointe, Dr. Wild served as executive vice president of Warner-Lambert and president of its pharmaceutical sector until the merger with Pfizer in June 2000. During his tenure, Dr. Wild had worldwide responsibility for Warner-Lambert's pharmaceutical commercial operations and research and development. Before joining Warner-Lambert in 1995, Dr. Wild spent 22 years with Schering-Plough Corporation in a number of positions across the globe, culminating as president of Schering-Plough's Japanese operations. Dr. Wild also served at Sandoz AG as a development chemist, where he worked on optimization and simulation of chemical processes. Dr. Wild is a member of the Board of Advisors to the Joseph L. Mailman School of Public Health at Columbia University, a Trustee of the Healthcare Institute of New Jersey, past Chairman of the International Section of Pharmaceutical Research and Manufacturers of America, and past Governor of the American Chamber of Commerce in Japan. Dr. Wild graduated from the University of York with a B.A. honors degree in Chemistry and received a Ph.D. in Physical Chemistry from the University of Cambridge | 